The transient progenitor-like nature of this population, coupled with the relatively weak oncogenic impact of ETV6-RUNX1, may explain the low rate of progression to ALL and the relatively good response of ETV6-RUNX1 ALL to chemotherapy. The gene discussed is ETV6; the disease is acute lymphoblastic leukemia.